What is Perspective Therapeutics's D&A?

Perspective Therapeutics (CATX) reported D&A of $1.13M in Q1 2026.

How has Perspective Therapeutics's D&A changed year-over-year?

Perspective Therapeutics's D&A increased by 53.8% year-over-year, from $732K to $1.13M.

What is the long-term trend for Perspective Therapeutics's D&A?

Over 2 years (2023 to 2025), Perspective Therapeutics's D&A has grown at a 81.6% compound annual growth rate (CAGR), from $986K to $3.25M.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Perspective Therapeutics CATX D&A

D&A at other companies

Eli LillyLLY

$509M+9.9%

ImmunomeIMNM

$603K-1.3%

Viridian Therapeutics, Inc.VRDN

$121K+3.4%

Lantheus HoldingsLNTH

$22.68M+66.5%

uniQureQURE

$2.96M-34.7%

PrecigenPGEN

$1.1M+74.7%

Other financials

Income statement

See full

Revenue$2.2M+27.3%

Gross profit$738.0K+78.3%

Operating income-$28.3M-29.5%

Net income-$26.2M-44.1%

EPS (diluted)-$0.250.0%

Balance sheet

See full

Cash & equivalents$54.0M+21.5%

Total debt$4.2M+10.9%

Total equity$347.4M+22.1%

Total assets$410.8M+24.7%

Cash flow

See full

Operating cash flow-$31.5M-45.8%

CapEx$6.9M+47.3%

Free cash flow-$38.3M-46.1%

Valuation

See full

Market cap$342.14M+33.2%

Enterprise value$292.34M+35.2%

P/S34.2×+19.6×

Profitability

See full

Gross margin33.1%-7.1pp

Operating margin-292.7%-553pp

Net margin-218.4%-781pp

FCF margin-1,073.3%—

Returns & leverage

See full

Return on equity-35.2%+2.3pp

Debt / equity0×0.0×

Current ratio8.7×-8.3×

Where this comes from

Reported directly by Perspective Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.

The official record: Perspective Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Perspective Therapeutics's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Perspective Therapeutics's D&A?: Perspective Therapeutics (CATX) reported D&A of $1.13M in Q1 2026.
How has Perspective Therapeutics's D&A changed year-over-year?: Perspective Therapeutics's D&A increased by 53.8% year-over-year, from $732K to $1.13M.
What is the long-term trend for Perspective Therapeutics's D&A?: Over 2 years (2023 to 2025), Perspective Therapeutics's D&A has grown at a 81.6% compound annual growth rate (CAGR), from $986K to $3.25M.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.